进口序贯国产利妥昔单抗治疗非霍奇金淋巴瘤的疗效及成本-效果分析

Efficacy and cost-effectiveness analysis of imported sequential domestic rituximab in treatment of non-Hodgkin’s lymphoma

目的分析进口序贯国产利妥昔单抗治疗非霍奇金淋巴瘤的疗效、安全性及成本-效果。方法回顾性分析2018年9月至2021年1月阜阳市人民医院收治的47例采用利妥昔单抗联合化疗方案治疗的非霍奇金淋巴瘤患者的临床资料,依据利妥昔单抗来源的不同,分为进口组(纯进口利妥昔单抗治疗)35例和序贯国产组(进口序贯国产利妥昔单抗治疗)12例。治疗3个疗程(3周为一个疗程)后,对比两组患者近期抗肿瘤疗效、治疗期间不良反应及患者成本-效果。随访6个月,比较两组患者累积生存率。结果治疗3个疗程后,两组患者缓解率对比,差异无统计学意义(P>0.05)。两组患者治疗期间并发症(疲劳、恶心呕吐、脱发、白细胞下降率)比较,差异均无统计学意义(P>0.05)。截止随访结束,进口组、序贯国产组累计生存率分别85.70%、83.30%,两组患者生存曲线比较差异无统计学意义(P>0.05)。进口组效果/成本比为522.32元,高于序贯国产组的274.92元,且每增加一个单位效果,比序贯国产组多付出8796.95元。结论进口序贯国产利妥昔单抗与纯进口利妥昔单抗治疗非霍奇金淋巴瘤的疗效、安全性及预后相近,但进口序贯国产利妥昔单抗治疗成本-效果优于单一使用进口利妥昔单抗。

Objective To analyze the efficacy,safety and cost-effectiveness of imported sequential domestic rituximab in the treatment of non-Hodgkin’s lymphoma.Methods The clinical data of 47 patients with non-Hodgkin’s lymphoma treated with rituximab combined with chemotherapy in Fuyang People’s Hospital from September 2018 to January 2021 were retrospectively analysed;based on the different rituximab sources,the patients were divided into the imported group(treated with pure imported rituximab)with 35 cases and the sequential domestic group(treated with imported sequential domestic rituximab)with 12 cases.After three courses of treatment,the short-term anti-tumor efficacy,adverse reactions during treatment,and patient cost-effectiveness were compared between the two groups.After 12 months of follow-up,the cumulative survival rates of the two groups were compared.Results After three courses of treatment,there was no statistically significant difference in the remission rate between the two groups of patients(P>0.05).In terms of the complications(fatigue,nausea and vomiting,hair loss,white blood cell decline rate)between the two groups of patients during treatment,there was no statistically significant difference(P>0.05).By the end of the follow-up,the cumulative survival rate of the imported group and the imported sequential domestic group was 85.70%and 83.30 respectively.there was no statistically significant difference in the survival curves between the two groups(P>0.05).The effect/cost ratio of the imported group and the sequential domestic group was 522.32 yuan and 274.92 yuan,respectively.The imported group was higher than the sequential domestic group,and each additional unit of effect would cost 8796.95 yuan more than the sequential domestic group.Conclusions Imported sequential domestic rituximab and pure imported rituximab have similar efficacy,safety and prognosis in the treatment of non-Hodgkin’s lymphoma,but imported sequential domestic rituximab treatment cost-effectiveness is better than thesingle use imported rituximab.